- Page 3 and 4:
Gerhard NahlerDictionary ofPharmace
- Page 5 and 6:
ForewordIn the beginning was the wo
- Page 7 and 8:
Foreword of the 1st editionThe evol
- Page 9 and 10:
IXPreface of the 1st editionFinally
- Page 11 and 12:
1abbreviated new drug application A
- Page 13 and 14:
3actual-treated analysis syn. as-tr
- Page 15 and 16:
5of a sign or symptom which is easi
- Page 17 and 18:
7allele frequency Often called gene
- Page 19:
9anecdotal study → see observatio
- Page 22 and 23:
12audaudit trail → see data trail
- Page 24 and 25:
14bento calculate the posterior odd
- Page 26 and 27:
16biolent; FDA: “bioequivalent dr
- Page 28 and 29:
18bloblock size Size of consecutive
- Page 30 and 31:
20caccachexia def. unintended and p
- Page 32 and 33:
22cascer patients); the method for
- Page 34 and 35:
24cemCE marking (of a medical devic
- Page 36 and 37:
26chrtain DNA and proteins; genes a
- Page 38 and 39:
28cleclerical error syn. key-punch
- Page 40 and 41:
30clijournals: Writing and editing
- Page 42 and 43:
32coithis treatment (e.g. to follow
- Page 44 and 45:
34comreporting”; → see also see
- Page 46 and 47:
36connal data. It should be possibl
- Page 48 and 49:
38conof exposure-outcome associatio
- Page 50 and 51:
40coopolymer matrix), wax matrices,
- Page 52 and 53:
42cosare increasingly used to facil
- Page 54 and 55:
44cumcumulative incidence Number of
- Page 56 and 57:
46datdata dredging Multiple, exhaus
- Page 58 and 59:
48datto confirm that the correct pr
- Page 60 and 61:
50devcomparison, e.g. two group par
- Page 62 and 63:
52diadiagnostic A product used for
- Page 64 and 65:
54disdisqualification rate → see
- Page 66 and 67:
56drudrug FDA: (1) substance recogn
- Page 68 and 69:
58druTable 1Determining the Probabi
- Page 70 and 71:
60ecbEC birth date First date on wh
- Page 72 and 73:
62effensures and declares that the
- Page 74 and 75:
64eleelectronic signature OECD: “
- Page 76 and 77:
66enzinformation about the physical
- Page 78 and 79:
68ethofficial action indicated; OAI
- Page 80 and 81:
70excglidants (improving powder flo
- Page 82 and 83:
72expin tabular or in graphic form
- Page 84 and 85:
74facfactorial design D. where it i
- Page 86 and 87:
76foomised, IIa walking distance >
- Page 88 and 89:
78gamgamma error syn. type III erro
- Page 90 and 91:
80gengeneric name syn. internationa
- Page 92 and 93:
82googood clinical research practic
- Page 94 and 95:
84halhalf life (t 1/2) Time within
- Page 96 and 97:
86heaprofiles are designed for a wi
- Page 98 and 99:
88icdICD-9 code International Class
- Page 100 and 101:
90impthey choose to submit manuscri
- Page 102 and 103:
92infbe given to the person signing
- Page 104 and 105:
94insincluding at least one member
- Page 106 and 107:
96intinternal audit → see audit.i
- Page 108 and 109:
98invinvestigational drug syn. inve
- Page 110 and 111:
100isoquality intentions concerning
- Page 112 and 113:
102kapKaplan-Meier method syn. prod
- Page 114 and 115:
104lablabelling FDA: “all labels
- Page 116 and 117:
106lifprotection; since costs of la
- Page 118 and 119:
108identified amount produced in a
- Page 120 and 121:
110masmaster file → see Drug Mast
- Page 122 and 123:
112medto the FDA by phone as soon a
- Page 124 and 125:
114micby chemicals; → see also an
- Page 126 and 127:
116monmonitor’s visit log list sy
- Page 128 and 129:
11890 days), certifies the dossier
- Page 130 and 131:
120natnational drug list syn. natio
- Page 132 and 133:
122nofno-fault insurance syn.: no-f
- Page 134 and 135:
124null-hypothesis (Ho) Statistical
- Page 136 and 137:
126oncgests carcinogenic potential,
- Page 138 and 139:
128outintroduced in Japan (limit: J
- Page 140 and 141:
130pacpackage insert → see patien
- Page 142 and 143:
132patpatient log list → see subj
- Page 144 and 145:
134perthe market authorisation stat
- Page 146 and 147:
136phaing price (USA 42%, Western a
- Page 148 and 149:
138phatics and observational, non-e
- Page 150 and 151:
140pheunder non-trial conditions; t
- Page 152 and 153:
142pooing conventional procedures o
- Page 154 and 155:
144powoccurs; → see also Individu
- Page 156 and 157:
146preassessments are harmonised (e
- Page 158 and 159:
148proproduct licence application (
- Page 160 and 161:
150rejected and not the confidence
- Page 162 and 163:
152quatice; it operates upon all me
- Page 164 and 165:
154racracemate equimolar mixture of
- Page 166 and 167:
156rarall member states; after the
- Page 168 and 169: 158refreference pricing syn. fixed
- Page 170 and 171: 160reprepeated measures design D. w
- Page 172 and 173: 162ressize of one or more measurabl
- Page 174 and 175: 164rougastric emtying; dermal: lipi
- Page 176 and 177: 166safsafety alert Voluntary commun
- Page 178 and 179: 168serof true positive plus false n
- Page 180 and 181: 170sinsingle-dose toxicity syn. acu
- Page 182 and 183: 172sporive from a study or any orga
- Page 184 and 185: 174staical trials; SOP should descr
- Page 186 and 187: 176strstrength of medication; amoun
- Page 188 and 189: 178subsubject identification code l
- Page 190 and 191: 180methods of s.a. are the actuaria
- Page 192 and 193: 182three-way crossover design → s
- Page 194 and 195: 184toxthe FDA still requests 12 mon
- Page 196 and 197: 186treon how long the desired effec
- Page 198 and 199: 188vacvaccine A preparation that co
- Page 200 and 201: 190as ideal drug and is distributed
- Page 202 and 203: 192welestablished in previous ratin
- Page 204 and 205: 194whowhich can be used because dru
- Page 206 and 207: 196xenotransplantation Animal-to-hu
- Page 208 and 209: 198zero order kinetics → see kine
- Page 210 and 211: 200ADRADRACADROITADRRSADsAdSADTAEAE
- Page 212 and 213: 202ASCOASIASMFASRAS-ODNATCATCCAUCAV
- Page 214 and 215: 204CADD Computer Assisted Drug Desi
- Page 216 and 217: 206ChBCHDCHFCHMPCHOCHOPCICIBCIMCIOM
- Page 220 and 221: 210DOBDoHD.P.DPMDRFDRLDSDDSMDSMBDSR
- Page 222 and 223: 212EPDEPhMRAEPLCePROEPSERERCPESCOPE
- Page 224 and 225: 214GHTFGIGILSPGITGLCGMGMCGM-CSFGMMG
- Page 226 and 227: 216ICD-9ICD-10ICDAICD-OICEICGEBICHI
- Page 228 and 229: 218LMWHLOCFLPILPOLRECLRTILUTILUTSLV
- Page 230 and 231: 220NANACDSNADNADANAFNAFTANAINAPMNAS
- Page 232 and 233: 222PCAPatient Controlled AnalgesiaP
- Page 234 and 235: 224RCGPRCCRCTR&DRDARDERDSREMRFPRHAR
- Page 236 and 237: 226StpSURSUSARSuspSVTTAATAPTBTBITCI
- Page 238 and 239: 228Selected bibliographyEuropean Co
- Page 240 and 241: 230WHOAdverse reaction dictionary.
- Page 242 and 243: 232Drug Research & Development1. Ph
- Page 244 and 245: 2344. The Practice of Medicinal Che
- Page 246 and 247: 2366. Practical Statistics for Medi
- Page 248 and 249: 2386. Medical Decision MakingSox H.
- Page 250 and 251: 240IFAPPInternational Federation of
- Page 252 and 253: 242http://www.infobiogen.fr/service
- Page 254: 244http://medicine.iupui.edu/flockh